In an article published by Clinical Leader, Dr. Artem A. Trotsyuk, partner at LongeVC, discusses how biotech founders can optimize their clinical trials for cost by running pre-trials with AI, utilizing synthetic data, and decentralizing trial operations.
As the technologies underpinning these operational improvements become mainstream, more clinical researchers will gain access to cost-effective trial approaches. It’s a shift that will benefit trial sponsors and participants alike.
Click here to read the full article in Clinical Leader.
As the technologies underpinning these operational improvements become mainstream, more clinical researchers will gain access to cost-effective trial approaches. It’s a shift that will benefit trial sponsors and participants alike.
Click here to read the full article in Clinical Leader.